Proteinopathies Program
Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) via prion-like protein spread
Key Facts
About Novoron Bioscience
Novoron Bioscience is a private, preclinical-stage biotech focused on unlocking the therapeutic potential of the Low-Density Lipoprotein Receptor (LDLR) family for CNS disorders. The company has built a proprietary toolbox and platform to develop selective modulators of receptors like LRP1, aiming to halt the spread of pathological proteins in diseases like Alzheimer's and to enhance regeneration after spinal cord injury. With a seasoned leadership team and scientific advisory board, Novoron is advancing its pipeline with a patient-centric philosophy that emphasizes thorough exploration to avoid false negatives. The company operates in large, underserved markets but faces significant scientific, clinical, and competitive risks inherent to novel CNS drug development.
View full company profile